Brief: Onxeo says cash position sufficient to fund development into H2 2017

Valerio Therapeutics SA

02/05/2016 17:00

May 2 (Reuters) - Onxeo SA  C4X.PA : 
    * Revenues for Q1 of 2016 totaled 782,000 euros ($900,473), 
compared with 918,000 euros in Q1 of 2015 
    * Q1 2016 recurring revenues were roughly flat compared to 
q1 2015 (755,000 euros compared with 761,000 euros in Q1 of 
2015) 
    * As of March 31, 2016, consolidated cash position amounted 
to 24.4 million euros, in line with expectations 
    * Current cash position is sufficient to fund development 
into second half of 2017 
 
Source text for Eikon:  ID:nBw3N5M6a  
Further company coverage:  C4X.PA  
 
($1 = 0.8684 euros) 
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))